title: CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.
abstract: OBJECTIVE
  Identifying antiretroviral therapy (ART) eligible HIV-infected (HIV+) pregnant women and rapidly initiating treatment preserves maternal health and prevents mother-to-child transmission. However, there have been few investigations of the performance of ART eligibility criteria in pregnant and postpartum women in resource-limited settings.
  
  
  METHODS
  Pregnant and recently postpartum HIV+ women received CD4+ cell count and World Health Organization (WHO) clinical staging at enrollment into the mother-to-child transmission Plus Initiative. We compared immunologic and clinical criteria based on 2009 WHO ART treatment guidelines (WHO stage 3/4 or CD4+ cell count ≤350 cells/mm³) in identifying ART eligible women.
  
  
  RESULTS
  Among 6036 women (62% antepartum, 38% postpartum), 2915 (48%) were ART eligible. Only 23% had WHO stage 3 or 4 disease, whereas 94% met CD4+ cell count criterion. Among 5356 women with WHO stage 1 or 2 disease, 2235 (42%) had CD4+ ≤350 cells per cubic millimeter. Change of CD4+ cell count ART eligibility threshold from ≤200 to ≤350 cells per cubic millimeter increased the proportion of ART eligible women from 21% to 45%.
  
  
  CONCLUSIONS
  Use of CD4+ cell count criterion is superior to clinical staging in identifying pregnant and postpartum HIV+ women eligible for ART. Improving access to CD4+ testing is essential to identify and treat eligible women, optimizing maternal and child health outcomes.
authors.affiliation: International Center for AIDS Care and Treatment Programs, Mailman School of Public Health, Columbia University, New York, NY 10032, USA. rc2315@columbia.edu
authors.forename: Rosalind J
authors.initials: RJ
authors.lastname: Carter
authors.forename: Kate
authors.initials: K
authors.lastname: Dugan
authors.forename: Wafaa M
authors.initials: WM
authors.lastname: El-Sadr
authors.forename: Landon
authors.initials: L
authors.lastname: Myer
authors.forename: Juliana
authors.initials: J
authors.lastname: Otieno
authors.forename: Nittaya
authors.initials: N
authors.lastname: Pungpapong
authors.forename: Patricia L
authors.initials: PL
authors.lastname: Toro
authors.forename: Elaine J
authors.initials: EJ
authors.lastname: Abrams
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D049590:Postpartum Period; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012720:Severity of Illness Index
chemical_list: D019380:Anti-HIV Agents